The TLR7 agonist Imiquimod promote the immunogenicity of msenchymal stem cells

BACKGROUND: Mesenchymal stem cells (MSCs) are considered the best candidate in stem cells therapy due to their multipotent differentiation ability, low expression of co-stimulatory molecules (CD80, CD86, CD34 and HLA-II) and immunosuppression effects on in vivo immune responses. MSCs were now widely...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Li, Liu, Dan, Pu, Dan, Wang, Yanwen, Li, Li, He, Yanqi, Li, Yalun, Li, Lei, Li, Weimin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4363195/
https://www.ncbi.nlm.nih.gov/pubmed/25654296
http://dx.doi.org/10.1186/0717-6287-48-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4363195/
https://www.ncbi.nlm.nih.gov/pubmed/25654296
http://dx.doi.org/10.1186/0717-6287-48-6

Ejemplares similares